Outcomes of venom-induced consumption coagulopathy following snakebite envenoming in Sudan: a cohort study Authors: Abdallateif A Omer, Abdelsalam M A Nail, Burhan A Mohammed, Rayan Ali Tonga, Tarig Elsammani Eisa, Fatima Altahir, Rania M H Baleela, GadAllah Modawe Published: 2026 ABSTRACT AbstractBackgroundSnakebite envenomation (SBE) is a major neglected tropical diseases, causing significant morbidity and mortality, particularly in sub-Saharan Africa. Venom-induced consumption coagulopathy (VICC) is a major systemic complication and leading cause of death in haemotoxic snakebite. In Sudan, SBE is underreported, and data on VICC in resource-limited settings remain scarce. This study aimed to determine the incidence, clinical and laboratory characteristics, management, and in-hospital outcomes of VICC in SBE patients, and to evaluate the performance of the 20-min whole blood clotting test (WBCT20) as a bedside screening tool.MethodsA hospital-based observational cohort study was conducted at Sinja Teaching Hospital, Sudan (15 March–15 September 2022). All consecutive SBE patients were included (n = 119). VICC was defined as INR ≥ 1.4 with prolonged PT and/or APTT. Data were collected using a structured questionnaire and routine clinical records. All patients underwent WBCT20 and standard coagulation testing. Outcomes included in-hospital mortality, acute kidney injury (AKI), severe haemorrhage, and length of stay. Analysis was descriptive using SPSS v25.ResultsOf 119 patients, 96 (80.7%) developed VICC. Most were young male farmers with lower limb bites (88.2%). Suspected Echis spp. accounted for 86.6% of cases. Spontaneous bleeding occurred in 88.5% of VICC patients, and severe haemorrhage in 30.2%, most commonly intracerebral bleeding. AKI occurred in 29.4% of all patients and only in those with VICC. WBCT20 was positive in all VICC cases (sensitivity 100%) and showed specificity of 89.6%, with 10 cases positive despite INR < 1.5, suggesting early coagulopathy. In-hospital mortality among VICC patients was 30.2%. All VICC patients received fresh frozen plasma, with clinical and laboratory improvement in 69.8%, though no comparative efficacy analysis was performed.ConclusionsVICC is highly prevalent among hospitalized SBE patients in this setting and is associated with major complications and high mortality. WBCT20 is a sensitive bedside tool but requires confirmation with laboratory testing. Findings highlight gaps in antivenom coverage, the need for species-appropriate therapy, and strengthened surveillance and prospective studies to improve snakebite management in Sudan.Keywords: Snakebites, Blood coagulation disorders, Haemorrhage, Acute kidney injury, Antivenins, Sudan Introduction Snakebite envenomation (SBE) is one of the most significant neglected tropical diseases (NTDs) in terms of incidence, severity, and clinical impact. It was recognized by the World Health Organization as one of the NTDs in 2017 [1, 2 ]. This was followed by the adoption of World Health Assembly resolution WHA 71.5 in 2018 and the subsequent launch of a global strategy in 2019 [3, 4 ] aimed at halving the burden of snakebite envenoming by 2030 [5]. In Sudan, 63,160 cases of snakebite were reported between 2014 and 2018, with an average annual incidence of 12,632 cases. The reported mortality rate among hospitalized patients during this period was 2.5% [6]. However, these figures likely underestimate the true burden of snakebite due to incomplete reporting and inadequate surveillance systems. Most snakebite victims in Sudan are agricultural workers and children, and the incidence increases during and following the rainy season, when snake activity is higher [6, 7 ]. Accurate estimation of snakebite incidence remains challenging, as many individuals seek care from traditional healers rather than medical facilities. Additionally, some victims die shortly after envenoming and are therefore not captured in hospital-based records, further contributing to underreporting. Snakebite envenoming (SBE) can cause both local and systemic consequences [8]. Local manifestations include skin damage such as blisters and necrosis, cellulitis, abscesses, and myonecrosis, which may occasionally require amputation [9]. Systemic complications include coagulopathy, nephrotoxicity, cardiotoxicity, myotoxicity, and neurotoxicity [10]. Among these, coagulopathy is the leading cause of death following snakebite and a major contributor to overall morbidity and mortality [11]. Venom-induced consumption coagulopathy (VICC) is the most common procoagulant disorder following SBE. It results from the activation of the clotting cascade at multiple factor points specific to the toxin of the offending snake species. The primary and potentially fatal consequence of VICC is haemorrhage [12]. During this process, clotting factors are consumed leaving few or none circulation, hence the term consumption coagulopathy [13, 14 ]. When appropriately managed, VICC develops rapidly, typically within hours of envenoming, and resolves within 24–48 h [15]. Clinical manifestations of VICC include spontaneous bleeding such as haematuria, gum bleeding, ecchymosis, and life-threatening haemorrhages including intracerebral haemorrhage, hematemesis, and pulmonary haemorrhage [16, 17 ]. The aim of this study was to determine the incidence, clinical characteristics, laboratory findings, management practices, and in-hospital outcomes of VICC among patients presenting with SBE at Sinja Teaching Hospital in Sennar State, Sudan. The study also sought to describe the performance of the 20-min whole blood clotting test (WBCT20) as a bedside screening tool for coagulopathy in this resource-limited setting. Methods Study design and setting This was an observational, hospital-based cohort study conducted at Sinja Teaching Hospital, Sinja City, Sennar State, Sudan. The study aimed to determine the incidence and outcomes of VICC among patients with snakebite envenoming. Ethical considerations Ethical approval for this study was obtained from the Ethical Committees of the Sudan Medical Specialization Board, the Sennar State Ministry of Health, and Sinja Teaching Hospital. Formal approval reference number: STH/Reference B/50/1. Written informed consent was obtained from all participants or from parents/legal guardians for minors before enrolment, including consent for publication of clinical details and clinical images where applicable. Study data were used exclusively for research purposes, and participant confidentiality was maintained through anonymization using serial identification numbers. Study population All patients admitted to the medical wards with a history of snakebite between 15 March 2022 and 15 September 2022 were eligible for inclusion. This study period encompassed both the dry season (March–May) and the rainy season (June–September) in Sudan, allowing capture of snakebite cases across different seasonal conditions. A total coverage sampling strategy was used due to the limited number of cases. Patients with known pre-existing coagulopathies or those receiving anticoagulant therapy were excluded. As this was an observational hospital-based study, all consecutive eligible snakebite patients presenting during the predefined study period were included. Therefore, no a priori sample size calculation or statistical power estimation was performed. The study sample was determined by the total number of eligible cases available during the study period. Data collection Data were collected using a structured questionnaire that included demographic characteristics, pictures of snake species, occupation, clinical history, site of envenoming, clinical features of coagulopathy, laboratory findings, treatment received, and outcomes. All patients underwent a detailed clinical examination and relevant laboratory investigations. Snake species identification Identification of the suspected offending snake species was attempted using pictorial aids depicting common haematotoxic snakes, provided by the herpetology curator, Sudan Natural History Museum, University of Khartoum. Species identification was based solely on patient self-report using these images, as snake specimens were not available for morphological or molecular confirmation. Assessment of coagulopathy Patients were categorized into VICC and non-VICC groups based on laboratory evidence of coagulopathy following SBE. VICC was defined as an international normalized ratio (INR) ≥ 1.4 together with prolonged coagulation parameters, including prothrombin time (PT) and/or activated partial thromboplastin time (APTT). Patients who did not meet these laboratory criteria were classified as non-VICC cases. Coagulation testing, including the WBCT20, PT, INR, and APTT, was performed at the time of hospital presentation as part of the routine clinical assessment of snakebite patients. Because this was an observational study, the interval between snakebite and hospital presentation varied among patients, and the timing of coagulation testing was therefore not standardized relative to the time of envenoming. The WBCT20 was performed in all patients as a point-of-care screening test. WBCT20 results were evaluated separately from the laboratory criteria used to define VICC. A positive WBCT20 was considered supportive evidence of coagulopathy but was not used as the sole diagnostic criterion. Patients with a positive WBCT20 but an INR <1.5 were considered to have possible early or evolving coagulopathy and were classified as non-VICC cases for the primary analysis. Laboratory procedures A total of 5 mL of venous blood was collected from each patient at presentation. 3 mL was used for routine laboratory investigations, including coagulation studies (PT, INR, APTT), complete blood count, and other clinically indicated tests. The remaining 2 mL was used for the WBCT20. For the WBCT20, freshly drawn venous blood was placed into a clean, dry syringe and left undisturbed at room temperature. After 20 min, the syringe was gently tilted once without agitation. Failure of the blood to clot, indicated by free flow of blood, was considered a positive test result suggestive of coagulopathy. Coagulation parameters (PT, INR, and APTT) were measured in the hospital laboratory using standard automated coagulation assays according to the manufacturer’s instructions and the laboratory’s standard operating procedures. These investigations were used to confirm the diagnosis and assess the severity of VICC. Routine internal quality control procedures were performed using control samples, and laboratory equipment was regularly calibrated and maintained in accordance with the hospital quality assurance protocols. Patients with suspected intracerebral haemorrhage underwent clinical neurological assessment and CT brain imaging when available and clinically indicated. However, due to loss of imaging records during the ongoing war in Sudan, neuroimaging findings could not be systematically reviewed nor incorporated into the analysis. Consequently, intracerebral haemorrhage reporting relied on documented clinical diagnoses and available medical records, which may have introduced diagnostic uncertainty and should be considered when interpreting our findings. Outcomes The primary outcome was in-hospital mortality among patients with VICC. Secondary outcomes included: Acute kidney injury (AKI). Acute kidney injury (AKI). Severe haemorrhage, defined as life-threatening bleeding including intracerebral haemorrhage, pulmonary haemorrhage, massive haemoptysis, haematemesis, or rectal bleeding. Severe haemorrhage, defined as life-threatening bleeding including intracerebral haemorrhage, pulmonary haemorrhage, massive haemoptysis, haematemesis, or rectal bleeding. Length of hospital stay. Length of hospital stay. Clinical recovery and discharge status. Clinical recovery and discharge status. Outcome data were recorded throughout hospitalization until discharge or death. Statistical analysis All data were entered and analszed using the Statistical Package for the Social Sciences (SPSS), version 25 (IBM Corp., Armonk, NY, USA). Given the descriptive nature of the study, analyses focused primarily on summarizing the demographic characteristics, clinical manifestations, laboratory findings, management, and outcomes of snakebite patients. Categorical variables are presented as frequencies and percentages, while continuous variables are presented as means with standard deviations or ranges, as appropriate. Patients were categorized into VICC and non-VICC groups based on predefined laboratory criteria. Median hospital stay was estimated manually from grouped frequency data using the grouped-data median formula: where L is the lower-class boundary of the median class, N is the total number of observations, CF is the cumulative frequency preceding the median class, f is the frequency of the median class, and h is the class width. Individual patient-level data were unavailable for calculation of the interquartile range. No formal hypothesis testing, univariate analyses, or multivariate regression models were performed. Therefore, associations between clinical characteristics and outcomes, including mortality, acute kidney injury, and severe haemorrhage, are descriptive and should not be interpreted as evidence of independent predictors or causal relationships. Results Patient characteristics and presentation A total of 119 patients with SBE were included in the study. Figure 1 is a flowchart that summarizes baseline assessment, treatment approaches and clinical outcomes. The mean age was 34.5 ± 9 years. Most patients were male (95/119, 79.8%). Farmers constituted the largest occupational group (52/119, 43.7%), followed by herdsmen (41/119, 34.5%). Ten of the patients were paediatric cases (10/119, 8.4%) and one of them was one year old. The lower limbs were the most common site of bite (105/119, 88.2%). As expected, snakebite cases showed a seasonal distribution, with 28 cases occurring in summer (March–May) (28/119, 23.5%) and 91 cases occurring in autumn (June–September) (91/119, 76.5%). Study flowchart illustrating patient selection, classification, management, and outcomes. Patients admitted with SBE at Sinja Teaching Hospital, Sudan (15 March–15 September 2022) were screened for eligibility and classified into VICC and non-VICC groups based on laboratory criteria. The figure summarizes baseline assessment, treatment approaches, clinical outcomes, and the final analysed cohort (N = 119) The majority of patients (90/119, 75.6%) arrived at the hospital on the same day as the snakebite. Delayed presentation was observed in 21 patients (17.6%), primarily due to initial consultation with traditional healers and in 8 patients (6.7%) due to transportation difficulty to reach hospital. Key demographic, clinical, and outcome characteristics are summarized in Table 1. Table 1Clinical and laboratory characteristics of patients with and without VICCVariableAll patients(n = 119)VICC(n = 96)Non-VICC(n = 23)Male sex, n (%)95 (79.8)78 (81.3)17 (73.9)Age, years (mean ± SD)34.5 ± 935 ± 833 ± 10Farmers, n (%)52 (43.7)46 (47.9)6 (26.1)Herdsmen, n (%)41 (34.5)––Paediatric patients, n (%)10 (8.4)10 (10.4)0 (0)Lower limb bites, n (%)105 (88.2)86 (89.6)19 (82.6)Same-day presentation, n (%)90 (75.6)71 (74.0)19 (82.6)Suspected Echis spp. bites, n (%)103 (86.6)89 (92.7)14 (60.9)Spontaneous systemic bleeding, n (%)85 (71.4)85 (88.5)0 (0)Bleeding from old healed wound, n (%)5 (5.2)5 (5.2)0 (0)Positive WBCT20, n (%)96 (80.7)96 (100)0 (0)INR ≥ 1.4, n (%)96 (80.7)96 (100)0 (0)Acute kidney injury, n (%)35 (29.4)35 (36.5)0 (0)Resolution of coagulopathy after FFP, n (%)–67/96 (69.8)–Mortality, n (%)29/119 (24.4)29/96 (30.2)0 (0)Median hospital stays, days (IQR)7.5 (5–7.7)7 (5–7.7)3 (not fully estimated) Clinical and laboratory characteristics of patients with and without VICC Snake identification and clinical outcomes Snake species identification was based on patient recognition using photographic aids, without morphological or molecular confirmation. Based on this approach, 103 patients (86.6%) identified Echis spp. as the suspected offending snake, while the species could not be identified in 16 cases (13.4%). Venom-induced consumption coagulopathy was diagnosed in 96 patients based on laboratory criteria, yielding a proportion of 80.7% among hospitalized SBE patients. Local swelling was documented among patients classified with VICC at the bite site within 30–60 min following envenoming. Prolonged bleeding from fang marks occurred in 79 of 96 patients (82.2%) (Fig. 2), while bleeding from a previously healed wound was observed in five patients (5.2%). Representative fang-mark lesions observed among patients with suspected Echis spp. envenoming. Yellow circles highlight the presumed bite sites identified during clinical examination. a Single puncture mark on the fourth toe of the left foot associated with localized swelling and discoloration. b Puncture mark on the palmar aspect of the right index finger. c Puncture mark located inferior to the medial malleolus of the right foot, surrounded by localized skin discoloration. Images were obtained at presentation and included in the study after informed consent. The identification of fang marks was based on clinical assessment and patient history consistent with recent snakebite envenoming Spontaneous systemic bleeding developed in 85 patients with VICC, frequently with multiple bleeding manifestations. These included gingival bleeding (85/96, 88.5%), hematuria (76/96, 79.2%), haemoptysis (40/96, 41.7%), ecchymosis (34/96, 35.4%, Fig. 3a), epistaxis (15/96, 15.6%), subconjunctival haemorrhage (14/96, 14.6%), and hematoma (3/96, 3.1%). Local tissue necrosis was also observed in patients identified as having been bitten by suspected Echis spp. (Fig. 3b). Representative clinical manifestations in patients with clinically suspected Echis spp. envenoming. a Extensive medial thigh ecchymosis associated with VICC. b Local tissue necrosis and severe swelling at the snakebite site on the foot, resulting in toe amputation. Images were recorded during routine clinical evaluation after informed consent and demonstrate both systemic haemorrhagic and local tissue-destructive effects observed in the study population Life-threatening haemorrhage occurred in 29 patients with VICC. Intracerebral haemorrhage was the most frequent manifestation (14/29, 48.3%), followed by hematemesis (5/29, 17.2%), massive haemoptysis (4/29, 13.8%), pulmonary haemorrhage (4/29, 13.8%), and rectal bleeding (2/29, 6.9%). The onset of clinical features of VICC varied; however, most patients developed symptoms within 2–12 h after envenoming (Fig. 4). Distribution of the time to onset of VICC following SBE (n = 96). Patients were categorized according to the interval between the reported time of snakebite and the first documented clinical evidence of VICC. Most patients (82%) developed VICC within 2–12 h of envenoming, whereas 15% developed manifestations within 2 h and 3% after 12 h. This finding indicates that clinical manifestations of coagulopathy generally occur during the first 12 h after envenoming Laboratory findings and diagnosis of VICC Venom-induced consumption coagulopathy was diagnosed using laboratory coagulation parameters. All 96 patients with VICC had an INR ≥ 1.4, prolonged prothrombin time, and prolonged activated partial thromboplastin time. The WBCT20 was positive in all patients with laboratory-confirmed VICC (sensitivity = 100%, specificity = 89.6%). Additionally, 10 patients (10.4%) demonstrated a positive WBCT20 despite an INR < 1.5, suggesting the presence of early or evolving coagulopathy; however, these patients did not meet the laboratory definition of VICC and were classified as non-VICC cases for the primary analysis. Among patients with VICC, 35 (36.4%) had an INR > 12, 41 (42.7%) had an INR between 8 and 12, and 20 (20.8%) had an INR between 1.5 and 7. Prothrombin time was prolonged in all VICC patients (mean 117.9 s; maximum 270 s), and APTT was similarly prolonged (mean 133.5 s). Platelet counts remained within the normal range throughout hospitalization (mean 290 × 103/µL). Haemoglobin levels were initially normal (mean 14 g/dL) but declined in 71 patients (74%); 12 patients (12.5%) developed haemoglobin levels below 8 g/dL and required packed red blood cell transfusion. White blood cell counts were within the normal range in 72 patients (75%) and elevated in 24 patients (25%), predominantly due to neutrophilia. Acute kidney injury (AKI) Acute kidney injury developed in 35 of 119 patients (29.4%). All AKI cases occurred in patients with laboratory-confirmed VICC, representing 36.5% of VICC cases. According to KDIGO criteria, 15 patients were classified as stage 1, 7 as stage 2, and 13 as stage 3 AKI. All patients who developed AKI had concomitant VICC. Management, hospital stay, and outcomes According to hospital policy, all patients with VICC received fresh frozen plasma (FFP) at a dose of 15 mL/kg. Clinical and laboratory resolution of VICC was observed in 67 patients (69.8%). Hospital length of stay varied, with most patients discharged within 5–7 days (Fig. 5). Among patients with VICC, 67 (69.8%) survived and were discharged, while 29 (30.2%) died. Thirteen deaths (13.5%) occurred between days 5 and 7 of admission, five (5.2%) between days 8 and 10, and 11 (11.5%) between days 11 and 16. Distribution of hospital length of stay among patients with VICC (N = 67). Treemap showing the proportion of patients according to total duration of hospitalization following admission for VICC. Length of stay was categorized into four intervals: 5–7 days (48%), 8–10 days (36%), 11–15 days (12%), and 15–30 days (4%). Each rectangle represents the relative proportion of patients within each hospitalization category, with area scaled to percentage frequency. Percentages were calculated using the total study population Ten paediatric patients (8.4% of the cohort) were included in the study. All paediatric patients in this small cohort died during 5–10 days of admission, including the youngest patient who was one year old. Given the limited number of paediatric cases, these findings should be interpreted with caution and are not sufficient to draw conclusions regarding paediatric mortality following SBE. The leading causes of death were intracerebral haemorrhage (45%) and complications related to acute kidney injury (38%) (Fig. 6). The median hospital stay before discharge was 7.7 days (estimated from grouped data). Distribution of causes of mortality among patients with VICC. Intracerebral haemorrhage (ICH) was the leading cause of death, followed by acute kidney injury (AKI), pulmonary haemorrhage (PH), upper gastrointestinal bleeding (UB), and retroperitoneal haemorrhage (RH) Antivenom administration and exposure classification The antivenom supplied by the National Medical Supplies Fund (Menaven/Biosnake, Vins Bioproducts Limited [18]) is formulated to neutralize the venoms of Naja naja, Naja nigricollis, and Cerastes cerastes and does not include Echis spp. antivenom, which was suspected in a substantial proportion of cases in this cohort. Antivenom availability was inconsistent during the study period, with adequate supplies typically available at the beginning of each month followed by shortages thereafter. Consequently, antivenom exposure was recorded descriptively based on actual administration rather than as a predefined intervention. Patients were categorized into three exposure groups according to treatment received: full standard dose, partial dose, or no antivenom (Table 2). This classification was used solely for descriptive analysis and does not represent a comparative treatment allocation framework. Table 2Antivenom exposure and outcomesAntivenom exposureNumber of patients (%)Deaths, n (%)Full dose41 (42.7)13 (31.7)Partial dose31 (32.3)11 (35.5)No antivenom24 (25.0)5 (20.8)Total9629 (30.2)n: number of patients Antivenom exposure and outcomes n: number of patients The full-dose regimen consisted of an initial loading dose of 6 vials of Vins BioSnake antivenom administered in 5 mL/kg normal saline infusion over one hour, followed by 2 vials administered every 6 h according to clinical response and availability. Discussion This study described the clinical characteristics, laboratory findings, management practices, and outcomes of VICC among 119 patients with SBE presenting to Sinja Teaching Hospital, Sudan, of whom 96 (80.7%) met the laboratory-based definition of VICC. Patients were followed from admission until discharge or death. The demographic profile of affected patients was comparable with previous reports from Sudan [6] and other snakebite-endemic settings in India and Asia [16, 17 ]. Most patients were young adult males involved in farming and livestock-related occupations, reflecting established occupational exposure patterns. The predominance of cases during the rainy season is similarly consistent with previous studies and likely reflects increased agricultural activity and greater human–snake interaction [16, 17, 19 ]. The proportion of patients developing VICC in this cohort (80.7%) was higher than that reported in studies from India, South Korea, and Sri Lanka [16, 17, 20,19 ]. Interpretation of this finding should be cautious because the study was conducted at a tertiary referral hospital that may receive disproportionately severe cases. Differences in referral pathways, access to care, disease severity at presentation, and availability of antivenom may also contribute to differences across settings. Snake identification in this study relied on patient recognition using standardized photographic aids and clinical assessment, without morphological, toxicological, or molecular confirmation. Current epidemiological data indicate that Echis pyramidum is among the principal medically important snake species in Sennar State [21, 22 ]. Although definitive species confirmation was not available, the predominance of suspected Echis envenoming in this cohort was supported by local epidemiology together with the observed clinical syndrome, including severe coagulopathy, prolonged PT and APTT, elevated INR values, spontaneous systemic bleeding, and acute kidney injury. These findings are consistent with the recognized haemotoxic effects of Echis venom [8, 9, 11 ]. Nevertheless, these manifestations are not specific to Echis bites, and species attribution should be interpreted cautiously. The most frequent clinical manifestations of VICC were prolonged bleeding from fang marks, gingival bleeding, and haematuria, findings similar to those reported from India and South Korea [16, 17, 19 ]. Life-threatening haemorrhage occurred in 30% of VICC patients, substantially higher than the 4–6.2% reported in studies from India and South Korea [16, 17, 19 ]. This higher rate may reflect delayed presentation, limited access to blood products, shortages of trained staff, and the absence of effective Echis-specific antivenom. All paediatric patients included in this cohort died during hospitalization. However, only ten paediatric cases were included, and this sample is too small to permit reliable conclusions regarding paediatric mortality risk. Nevertheless, this observation is consistent with broader literature suggesting poorer outcomes among children following SBE [23]. Proposed explanations include greater venom exposure relative to body weight, delays in presentation, and barriers to timely access to effective treatment. Laboratory findings in patients with VICC were consistent with previous descriptions of consumptive coagulopathy following haemotoxic snakebite [16, 17, 19 ]. All VICC cases demonstrated prolonged coagulation parameters and INR ≥ 1.4, while platelet counts remained largely preserved. Severe coagulation abnormalities and acute kidney injury were commonly observed among patients with adverse outcomes, although this study was not designed to determine independent predictors of mortality. The WBCT20 demonstrated high sensitivity (100%) and moderate specificity (89.6%) when evaluated against the laboratory-based definition of VICC. Additionally, 10 patients had a positive WBCT20 despite INR values below the diagnostic threshold, suggesting possible early or evolving coagulopathy. These findings support the continued role of WBCT20 as a rapid bedside screening tool in resource-limited settings [24, 25 ] where laboratory testing may not be immediately available. Findings from the present study are consistent with evidence from Nigeria, where the 20WBCT demonstrated high sensitivity for detecting VICC in Echis ocellatus envenoming, although with limited specificity and occasional false-positive results. The Nigerian study also highlighted the utility of repeated 20WBCT testing to identify evolving, persistent, or rebound coagulopathy, supporting its role as a practical bedside screening tool in resource-limited settings despite its diagnostic limitations [26]. However, WBCT20 should not be used in isolation and should be interpreted together with clinical assessment and laboratory coagulation studies whenever possible. Because disposable syringes rather than standardized glass tubes were used in our setting, clotting performance may differ from standardized protocols and should be interpreted accordingly. Antivenom supplied during the study period was a polyvalent formulation designed for Naja and Cerastes species and did not provide coverage for suspected Echis envenoming. In addition, availability was inconsistent throughout the study period. Antivenom exposure was therefore recorded descriptively according to routine clinical practice and not as a predefined therapeutic comparison. Fresh frozen plasma was administered to all patients with VICC as part of routine clinical care. Clinical and laboratory improvement was observed in approximately 70% of patients during hospitalization, typically within 5–7 days. Previous evidence suggests limited support for the use of heparin in VICC, while FFP may be beneficial mainly in patients with active bleeding [9]. However, because all patients in our cohort received FFP and no comparison group was available, this observational study was not designed to evaluate treatment effectiveness. Therefore, the observed recovery cannot be attributed directly to FFP, and no conclusions can be drawn regarding its impact on clinical outcomes. Previous studies suggest that clotting factor replacement may have limited benefit when coagulopathy persists due to ongoing venom activity. For example, a retrospective study from Southern China reported no clear improvement in coagulation recovery following administration of FFP and/or cryoprecipitate after antivenom in patients with green pit viper envenoming, although these findings may not be generalizable across snake species and envenoming syndromes [27]. Accordingly, treatment-related findings in the present study should be interpreted cautiously. Because species-appropriate antivenom was not consistently available and no comparative treatment analysis was performed, clinical outcomes cannot be attributed to FFP administration. These observations are consistent with current recommendations emphasizing timely administration of effective antivenom to neutralize venom activity, while supportive therapies should be interpreted within the broader clinical context. Mortality among patients with VICC was 30.2%, which exceeded rates reported in several international cohorts [16, 17, 19 ]. Interpretation of these differences requires caution because healthcare systems, ICU access, antivenom availability, referral mechanisms, and case severity differ substantially across settings. Globally, snakebite mortality shows marked regional variation and is disproportionately concentrated in low- and middle-income regions, with the highest burden reported in South Asia and persistently elevated mortality across sub-Saharan Africa. Previous global estimates have also demonstrated an inverse relationship between socio-demographic development and snakebite mortality, suggesting that health system capacity and access to timely care are important determinants of outcome [28]. In our cohort, deaths occurred predominantly among patients with severe haemorrhagic complications and acute kidney injury; however, causal relationships cannot be inferred because of the observational design and lack of multivariable analysis. In addition, incomplete information regarding dialysis requirements and access to renal replacement therapy limited assessment of the contribution of renal failure to mortality. The findings of this study should also be interpreted within the context of a tertiary referral centre serving a large snakebite-endemic region. Referral bias and severity-selection bias may have contributed to overrepresentation of severe cases and adverse outcomes. Consequently, the incidence of VICC, complication rates, and mortality observed in this cohort may not reflect the broader spectrum of SBE in the country. Finally, this study provides descriptive evidence on the burden and clinical profile of VICC in a resource-limited setting in Sudan. Given the observational design, findings should be interpreted as associations rather than causal relationships. These results highlight the need for improved access to species-appropriate antivenom, strengthened referral systems, standardized diagnostic approaches, and prospective multicentre studies to better define predictors of adverse outcomes and optimize snakebite management. Limitations Snake species identification relied on patient self-report supported by photographic aids and was therefore susceptible to recall bias and misclassification. The absence of morphological or molecular confirmation limited accurate species-level identification. Here, VICC was confirmed using laboratory coagulation parameters (INR, PT, and APTT), while WBCT20 was used as the bedside screening tool. Although WBCT20 demonstrated high sensitivity (100%) and good specificity (89.6%) in this cohort, 10 patients had a positive WBCT20 despite an INR < 1.5, suggesting possible early or evolving coagulopathy and indicating the limitations of using WBCT20 alone. Additionally, the use of disposable syringes instead of standardized glass tubes may have affected clot formation and introduced measurement bias. No univariate or multivariate analyses were performed to identify independent predictors of mortality, AKI, or severe haemorrhage. Given the descriptive study design and limited sample size, the cohort was not adequately powered for robust multivariable modelling. Consequently, observed associations should be interpreted as descriptive rather than causal. Standardized severity grading was also not routinely applied during the study period. Antivenom availability was inconsistent throughout the study period, and the available polyvalent antivenom lacked coverage against the predominant local Echis species. Therefore, the effectiveness of species-appropriate antivenom therapy could not be assessed. Fresh frozen plasma was administered according to local clinical practice despite limited antivenom coverage, which may have influenced interpretation of treatment-related outcomes. Furthermore, detailed information regarding transfusion practices beyond FFP—including indications, timing, volume, and use of packed red blood cells, platelets, or cryoprecipitate—was incompletely recorded, preventing assessment of their contribution to outcomes. Precise time-to-presentation data were not systematically recorded, limiting evaluation of delayed presentation on outcomes and preventing meaningful comparisons between early and late presenters. In addition, prehospital factors—including traditional treatments, prior fluid administration, and care received at peripheral facilities—were not systematically captured and may have influenced disease severity and subsequent outcomes. Potential confounding from concurrent conditions such as sepsis, dehydration, underlying comorbidities, and other acute illnesses could not be assessed and may have contributed independently to coagulation abnormalities, AKI, prolonged hospitalization, and mortality. As this was a single-centre tertiary referral hospital study in a snakebite-endemic region of Sudan, referral and severity-selection bias likely resulted in overrepresentation of severe cases. Consequently, estimates of VICC incidence, complications, and mortality may not reflect the broader snakebite population. In addition, the limited number of paediatric patients and absence of post-discharge follow-up restricted assessment of long-term outcomes, including progression from AKI to chronic kidney disease and other late complications. Multi-centre prospective studies with standardized data collection are needed to improve generalizability and identify independent predictors of adverse outcomes. Conclusions Among patients with SBE admitted to this tertiary referral hospital in Sudan, laboratory-defined VICC was frequently observed and was associated with systemic bleeding, AKI, prolonged hospitalization, and mortality. These findings describe the clinical profile and outcomes of hospitalized patients and should not be interpreted as estimates of population-level incidence. Most cases were clinically consistent with haemotoxic envenoming and were attributed to suspected Echis spp. based on patient recognition and clinical presentation; however, definitive species confirmation was not available. The WBCT20 showed high sensitivity as a bedside screening tool for coagulopathy in this setting but should be interpreted alongside laboratory coagulation testing whenever available. Fresh frozen plasma was widely used as part of routine clinical care, although this study was not designed to evaluate treatment effectiveness. The findings should be interpreted cautiously because of the descriptive design, limited sample size, referral bias, incomplete treatment data, absence of standardized severity grading, and limited species confirmation. Further prospective, multicentre studies incorporating standardized severity assessment, comprehensive treatment documentation, and access to species-appropriate antivenom are needed to better characterize predictors of adverse outcomes and optimize management of VICC in Sudan and similar resource-limited settings. Recommendations In line with the WHO target to reduce snakebite-related mortality and disability by 50% by 2030, improving outcomes of VICC in Sudan requires coordinated action across clinical care, antivenom access, community awareness, and surveillance. Efforts should be directed towards ensuring a reliable supply of quality-assured antivenom with coverage against locally prevalent medically important snake species, particularly Echis spp., which was clinically suspected in most cases in this cohort. Antivenom procurement and distribution should be guided by local epidemiology and species distribution. Community awareness programmes should promote early hospital presentation and discourage delays associated with traditional treatment practices, especially during peak snakebite seasons. Strengthening referral pathways and transport systems between rural communities and higher-level healthcare facilities may improve timely access to care. Diagnostic capacity for VICC should be strengthened through standardized implementation of the WBCT20, supported by laboratory coagulation testing where available. National clinical guidelines should emphasize evidence-based use of antivenom, careful administration of blood products, and timely recognition and referral of severe complications, including intracerebral haemorrhage and acute kidney injury. Healthcare facilities managing SBE should be supported with adequate supplies, staff training, and continuing professional education in snakebite recognition and management. Future research should prioritize prospective multicentre studies, standardized severity grading, improved documentation of transfusion practices and prehospital care, and more accurate snake identification using morphological or molecular approaches. Establishment of regional snakebite surveillance systems would support evidence-based planning, monitoring of outcomes, and optimization of snakebite management strategies in Sudan. Summary Snakebite envenomation remains a serious but underrecognized health problem in Sudan, particularly among rural farming communities. This study examined patients admitted with snakebite at a major hospital in Sennar State to understand how often a dangerous bleeding disorder, venom-induced consumption coagulopathy (VICC), occurs and what outcomes patients experience. We found that most hospitalized patients developed VICC, a condition that causes severe disruption of blood clotting and can lead to spontaneous bleeding, organ failure, and death. Nearly one-third of affected patients died in hospital, with brain haemorrhage and kidney failure being the most common causes of death. Most cases were linked to suspected Echis species bites. A simple bedside test (WBCT20) correctly identified all patients with coagulopathy, suggesting it is useful in settings where laboratory testing is limited, although it may occasionally give early positive results before full disease develops. Fresh frozen plasma was widely used, but its effect could not be definitively assessed due to the observational design. Our findings highlight a high burden of severe snakebite complications in this setting and emphasize the urgent need for better access to appropriate antivenom, earlier hospital presentation, and stronger health system support for snakebite management in Sudan. Acknowledgements The authors acknowledge Ms. Entisar Khider, a herpetologist and molecular biologist at the Sudan Natural History Museum, Faculty of Science, University of Khartoum, the patients who participated in this study and the staff of Sinja Teaching Hospital, Sennar State, Sudan. Abbreviations Acute kidney injury Activated partial thromboplastin time Fresh frozen plasma International normalized ratio Kidney Disease: Improving Global Outcomes criteria Neglected tropical diseases Prothrombin time Venom-induced consumption coagulopathy 20-Min whole blood clotting test Author contributions AO conceived the study, contributed to study design, and participated in manuscript preparation. AN and BM coordinated study implementation, supervised data collection, and contributed to methodology development. RT and TE contributed to patient recruitment, clinical investigation, data acquisition, and resource provision. FA and GM developed the methodology, performed data analysis and interpretation, and contributed to statistical analysis. RB contributed to data visualization and critical review of the manuscript. AN, BM, RT, TE, FA, and GM curated the dataset and conducted the investigation. AO, AN, BM, RT, TE, FA, and GM prepared the original manuscript draft. AO, RT, TE, FA, RB, and GM contributed to manuscript review and editing. All authors reviewed, approved the final manuscript, and agreed to be accountable for all aspects of the work. Funding This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Data availability All data supporting the findings of this study are available within the paper and its Supplementary Information. Declarations Ethics approval and consent to participate Ethical approval was obtained from the Ethics Committees of the Sudan Medical Specialization Board, Sennar State Ministry of Health, and Sinja Teaching Hospital (Ref: STH/Reference B/50/1). Administrative approval was secured before study initiation. Consent for participation was collected from all study participants or their guardians prior to their involvement in the research. Participants were informed of the study’s purpose, procedures, and potential risks. They were assured that their participation was voluntary and that their personal information would remain confidential. Written consent was obtained before data collection began. Consent for publication All authors have read and agreed to the published version of the manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data supporting the findings of this study are available within the paper and its Supplementary Information.